• Our Solution
    • Physicians
    • Patients
  • About Artrya
    • Who we are
    • Leadership Team
    • Board of Directors
    • Careers
  • Investor Relations
    • Overview
    • ASX Announcements
    • Corporate Governance
    • Company Research
  • Contact Us
Request a demonstration

Annual Report to shareholders

Notice of Annual General Meeting/Proxy Form

Response to Price and Volume Query

Company Presentation – October 2024

Notification of cessation of securities – AYA

Issue of Shares on RSU Exercise and Cleansing Notice

Application for quotation of securities – AYA

Artrya Submits 510(k) Application to US FDA

Appendix 4E and Annual Financial Statements June 2024

AYA on track for FDA application submission following Q-sub

Previous 1 2 3 4 5 Next

Precise diagnosis. Personalized treatment.
Preventative care.

Choose Artrya as your trusted clinical partner.

Contact us today
Coronary artery disease.
We see you.

Sign up to our newsletter

Request a Demo
Contact Us

About Artrya
Investor Relations

Location
1257 Hay Street, West Perth, 6005
Follow us
X
LinkedIn

Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods, ID 347719.  Salix Coronary Anatomy USA product (K243038) is cleared in the USA. 
For the availability of Salix in the EU, UK, US or other jurisdictions, please contact us.

© 2025, Artrya. All rights reserved. Privacy Policy Terms and Conditions Indications for Use